The FDA approved the expanded use of GlaxoSmithKline's Havrix (hepatitis A vaccine, inactivated) for the prevention of hepatitis A in children aged 12 months and older. Havrix was previously approved by the FDA for use in children ages two through 18 years. This expanded indication will allow healthcare practitioners to vaccinate younger children against hepatitis A with Havrix.
Esprit Pharma acquired exclusive North American rights to Estrasorb (estradiol topical emulsion) from Novavax. A topical emulsion form of the naturally occurring hormone beta-estradiol 17, Estrasorb is the first prescription topical emulsion for estrogen therapy.
Upsher-Smith Laboratories introduced new Vandazole (metronidazole vaginal gel, 0.75 percent) for treatment of bacterial vaginosis in non-pregnant patients.